Evaluating infectious disease prevention over the long term: implications of analytic horizon and scenario choices
A lifetime time horizon is conventional for cost-effectiveness analysis, but not routine for transmission-dynamic modeling given uncertainty in epidemiological dynamics and high computational costs. We demonstrate how choices about time horizon and analytic scenarios can influence cost-effectiveness estimates, using a case study of novel tuberculosis (TB) vaccine introduction.